HB 144 amends Texas law to treat unborn children as legal persons under criminal and civil law from fertilization onward. It redefines "individual" in the Penal Code to include unborn children and adds provisions requiring criminal statutes to apply equally to offenses against unborn children, while excluding unintentional harm from lifesaving medical procedures for the mother or spontaneous miscarriages. The bill repeals existing legal exceptions that permitted "prenatal homicide" and laws that could be interpreted as enabling pressure on pregnant people to obtain abortions. It directly affects medical providers, legal proceedings involving pregnancy-related injuries, and individuals seeking civil remedies for harm to unborn children.
HB 7, the Woman and Child Protection Act, prohibits the manufacture and provision of abortion-inducing drugs in Texas while limiting legal actions against certain local providers. It creates new legal protections for Texas-based hospitals, health facilities, and providers who practice exclusively within the state, shielding them from civil lawsuits under this law. The bill also restricts courts outside Texas from enforcing judgments related to abortion drugs and allows private citizens to file lawsuits ("qui tam actions") against violators. It directly affects drug manufacturers, pharmacies, and healthcare entities offering abortion-inducing drugs, but excludes Texas hospitals, state facilities, and in-state-only providers from liability. The law takes effect immediately upon the governor’s signature.
SB 7 creates civil liability for manufacturers and providers of abortion-inducing drugs, with key exemptions for medical emergencies, ectopic pregnancies, and spontaneous miscarriages. It allows private citizens to file lawsuits (qui tam actions) seeking damages against those supplying such drugs, while modifying fee-shifting rules in abortion litigation. The bill also grants the Texas attorney general expanded authority to pursue cases under the "Woman and Child Protection Act" and alters jurisdiction for related court cases. It does not restrict medical procedures covered by the specified exemptions.
This joint resolution proposes a constitutional amendment to repeal the Dementia Prevention and Research Institute of Texas and its dedicated fund. It would redirect $3 billion from that fund to the Texas Education Agency to reduce property taxes through lower state compression percentages. If approved by voters in the November 2025 election, the amendment would eliminate dedicated dementia research funding while shifting those resources to property tax relief. The bill does not change existing dementia research programs but redirects existing funding to a different state priority.
HB 131 repeals the Dementia Prevention and Research Institute of Texas and transfers its funds to the Texas Education Agency. The transferred money would be used to reduce state property tax rates for homeowners. This bill only takes effect if voters approve a related constitutional amendment in 2025; otherwise, it has no legal impact. The legislation directly affects state funding allocations and property tax policy, with no changes to dementia research programs.
HB 127 prohibits Texas state agencies from promoting "diversity, equity, and inclusion" (DEI) or LGBTQ-related content in their operations. The bill requires agencies to treat people equally regardless of race, color, or national origin, while mandating that all actions comply with the "biological reality" that sex is strictly male or female. Key mechanisms include voiding any agency policies, curricula, or contracts violating these rules, and banning DEI initiatives as "null and void ab initio." The bill directly affects all Texas state agencies, including education, health, and government departments, by restricting how they develop policies or communicate with the public. It takes effect immediately if approved by a two-thirds vote in both legislative chambers, or 91 days after the session ends.
HB 82 prohibits the distribution of abortion-inducing drugs within Texas, targeting individuals or entities that manufacture, mail, transport, deliver, prescribe, or provide such drugs. It directly affects abortion providers, distributors, and those who facilitate access to these drugs, while excluding internet service providers, search engines, and cloud service providers from liability under the law. The bill creates a private civil right of action, allowing individuals to sue violators for damages related to the distribution of abortion-inducing drugs. These provisions are codified under the new "Women and Child Protection Act" in the Health and Safety Code.
HB 151 designates carisoprodol (a muscle relaxant), mifepristone, and misoprostol as Schedule IV controlled substances under Texas law. This change would subject these substances to stricter regulation, including prescription requirements and penalties for unauthorized possession or distribution. The bill takes effect January 1, 2026, applying only to offenses committed on or after that date, with prior offenses governed by existing law. It directly affects individuals and providers handling these substances in Texas, requiring compliance with Schedule IV controls.
HB 80 imposes civil liability on individuals or entities distributing abortion-inducing drugs and requires internet service providers to take specific actions related to such content. The bill creates a new criminal offense for violations and authorizes private individuals to file civil lawsuits for breaches of the law. This legislation directly affects distributors of abortion drugs, internet service providers, and those involved in civil litigation under the new provisions. Note: Specific details of the internet service provider duties and criminal offense are not provided in the available bill text.
This bill allows Texas pharmacists to dispense ivermectin without a doctor's prescription. It requires the state health commissioner to issue a statewide order with standardized protocols, patient instructions, and annual reporting on dispensing volumes. Pharmacists acting in good faith under this order are protected from legal liability. The law directly affects licensed pharmacists and patients seeking ivermectin through pharmacy channels.
